BIOMAT Database Logo BIOMAT Database Logo

Selective immunosuppression of tumour necrosis factor-alpha in rheumatoid arthritis. 1995

F M Brennan, and A P Cope, and P Katsikis, and D L Gibbons, and R N Maini, and M Feldmann
Kennedy Institute of Rheumatology, Hammersmith, London, UK.

UI MeSH Term Description Entries
D007165 Immunosuppression Therapy Deliberate prevention or diminution of the host's immune response. It may be nonspecific as in the administration of immunosuppressive agents (drugs or radiation) or by lymphocyte depletion or may be specific as in desensitization or the simultaneous administration of antigen and immunosuppressive drugs. Antirejection Therapy,Immunosuppression,Immunosuppressive Therapy,Anti-Rejection Therapy,Therapy, Anti-Rejection,Therapy, Antirejection,Anti Rejection Therapy,Anti-Rejection Therapies,Antirejection Therapies,Immunosuppression Therapies,Immunosuppressions,Immunosuppressive Therapies,Therapies, Immunosuppression,Therapies, Immunosuppressive,Therapy, Immunosuppression,Therapy, Immunosuppressive
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D001172 Arthritis, Rheumatoid A chronic systemic disease, primarily of the joints, marked by inflammatory changes in the synovial membranes and articular structures, widespread fibrinoid degeneration of the collagen fibers in mesenchymal tissues, and by atrophy and rarefaction of bony structures. Etiology is unknown, but autoimmune mechanisms have been implicated. Rheumatoid Arthritis
D014409 Tumor Necrosis Factor-alpha Serum glycoprotein produced by activated MACROPHAGES and other mammalian MONONUCLEAR LEUKOCYTES. It has necrotizing activity against tumor cell lines and increases ability to reject tumor transplants. Also known as TNF-alpha, it is only 30% homologous to TNF-beta (LYMPHOTOXIN), but they share TNF RECEPTORS. Cachectin,TNF-alpha,Tumor Necrosis Factor Ligand Superfamily Member 2,Cachectin-Tumor Necrosis Factor,TNF Superfamily, Member 2,TNFalpha,Tumor Necrosis Factor,Cachectin Tumor Necrosis Factor,Tumor Necrosis Factor alpha
D015847 Interleukin-4 A soluble factor produced by activated T-LYMPHOCYTES that induces the expression of MHC CLASS II GENES and FC RECEPTORS on B-LYMPHOCYTES and causes their proliferation and differentiation. It also acts on T-lymphocytes, MAST CELLS, and several other hematopoietic lineage cells. B-Cell Growth Factor-I,B-Cell Stimulatory Factor-1,Binetrakin,IL-4,Mast Cell Growth Factor-2,B Cell Stimulatory Factor-1,B-Cell Growth Factor-1,B-Cell Proliferating Factor,B-Cell Stimulating Factor-1,B-Cell Stimulatory Factor 1,BCGF-1,BSF-1,IL4,MCGF-2,B Cell Growth Factor 1,B Cell Growth Factor I,B Cell Proliferating Factor,B Cell Stimulating Factor 1,B Cell Stimulatory Factor 1,Interleukin 4,Mast Cell Growth Factor 2
D016207 Cytokines Non-antibody proteins secreted by inflammatory leukocytes and some non-leukocytic cells, that act as intercellular mediators. They differ from classical hormones in that they are produced by a number of tissue or cell types rather than by specialized glands. They generally act locally in a paracrine or autocrine rather than endocrine manner. Cytokine
D016212 Transforming Growth Factor beta A factor synthesized in a wide variety of tissues. It acts synergistically with TGF-alpha in inducing phenotypic transformation and can also act as a negative autocrine growth factor. TGF-beta has a potential role in embryonal development, cellular differentiation, hormone secretion, and immune function. TGF-beta is found mostly as homodimer forms of separate gene products TGF-beta1, TGF-beta2 or TGF-beta3. Heterodimers composed of TGF-beta1 and 2 (TGF-beta1.2) or of TGF-beta2 and 3 (TGF-beta2.3) have been isolated. The TGF-beta proteins are synthesized as precursor proteins. Bone-Derived Transforming Growth Factor,Platelet Transforming Growth Factor,TGF-beta,Milk Growth Factor,TGFbeta,Bone Derived Transforming Growth Factor,Factor, Milk Growth,Growth Factor, Milk
D016753 Interleukin-10 A cytokine produced by a variety of cell types, including T-LYMPHOCYTES; MONOCYTES; DENDRITIC CELLS; and EPITHELIAL CELLS that exerts a variety of effects on immunoregulation and INFLAMMATION. Interleukin-10 combines with itself to form a homodimeric molecule that is the biologically active form of the protein. IL-10,CSIF-10,Cytokine Synthesis Inhibitory Factor,IL10,Interleukin 10
D018124 Receptors, Tumor Necrosis Factor Cell surface receptors that bind TUMOR NECROSIS FACTORS and trigger changes which influence the behavior of cells. Cachectin Receptors,TNF Receptors,Tumor Necrosis Factor Receptors,Receptors, Cachectin,Receptors, TNF,TNF Receptor,Tumor Necrosis Factor Receptor,Receptor, TNF

Related Publications

F M Brennan, and A P Cope, and P Katsikis, and D L Gibbons, and R N Maini, and M Feldmann
Treating rheumatoid arthritis with tumour necrosis factor alpha blockade.
February 2002, BMJ (Clinical research ed.),
F M Brennan, and A P Cope, and P Katsikis, and D L Gibbons, and R N Maini, and M Feldmann
Tumour necrosis factor blockade in rheumatoid arthritis.
January 2001, Clinical medicine (London, England),
F M Brennan, and A P Cope, and P Katsikis, and D L Gibbons, and R N Maini, and M Feldmann
Beneficial effects of tumour necrosis factor-alpha (TNF-alpha) blockade in rheumatoid arthritis (RA)
August 1995, Clinical and experimental immunology,
F M Brennan, and A P Cope, and P Katsikis, and D L Gibbons, and R N Maini, and M Feldmann
[Tumour necrosis factor alpha antagonists in established rheumatoid arthritis: effectiveness comparative study].
May 2010, Medicina clinica,
F M Brennan, and A P Cope, and P Katsikis, and D L Gibbons, and R N Maini, and M Feldmann
Peptostreptococcal pericarditis complicating anti-tumour necrosis factor alpha treatment in rheumatoid arthritis.
July 2002, Annals of the rheumatic diseases,
F M Brennan, and A P Cope, and P Katsikis, and D L Gibbons, and R N Maini, and M Feldmann
Blockade of tumour necrosis factor-alpha in rheumatoid arthritis: effects on components of rheumatoid cachexia.
December 2007, Rheumatology (Oxford, England),
F M Brennan, and A P Cope, and P Katsikis, and D L Gibbons, and R N Maini, and M Feldmann
Tumour necrosis factor-alpha blockers in rheumatoid arthritis: review of the clinical experience.
January 2001, BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy,
F M Brennan, and A P Cope, and P Katsikis, and D L Gibbons, and R N Maini, and M Feldmann
A tumour necrosis factor alpha polymorphism is not associated with rheumatoid arthritis.
July 1995, Annals of the rheumatic diseases,
F M Brennan, and A P Cope, and P Katsikis, and D L Gibbons, and R N Maini, and M Feldmann
Anti-tumour necrosis factor alpha therapy in rheumatoid arthritis: an update on safety.
December 2004, Annals of the rheumatic diseases,
F M Brennan, and A P Cope, and P Katsikis, and D L Gibbons, and R N Maini, and M Feldmann
Rheumatoid arthritis and tumor necrosis factor alpha.
January 2001, Autoimmunity,
Copied contents to your clipboard!